Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy (ENDOTK)
Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy: A Randomized Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
NRW
-
Essen, NRW, Germany, 45276
- Evang. Kliniken Essen-Mitte
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological diagnosed breast cancer (Stage I-III), no metastases
- Current endocrine therapy (minimum 3 months)
- Score of 9 or greater on the Menopausal Rating Scale (MRS)
- Signed informed consent
Exclusion Criteria:
- Severe other somatic or psychiatric comorbidity
- Pregnancy
- Planned or existing chemotherapy, radiation or other cure treatment
- Participation in other clinical studies with behaviour-oriented, psychological or compementary medicine intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Mind body medicine day care clinic
Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
|
Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
|
|
Other: Usual care
Patients continue usual care by their practitioner
|
Patients continue usual care by their practitioner
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Menopausal symptoms
Time Frame: week 11
|
Menopause Rating Scale (MRS)
|
week 11
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
General health-related quality of life
Time Frame: week 11
|
Functional Assessment of Cancer Therapy - General Questionaire (FACT-G)
|
week 11
|
|
Spiritual health-related quality of life
Time Frame: week 11
|
Functional Assessment of Cancer Therapy - Spirutual Subscale (FACT-SP)
|
week 11
|
|
Fatigue
Time Frame: week 11
|
Functional Assessment of Cancer Therapy - Fatigue Subscale (FACT-F)
|
week 11
|
|
Mental wellbeing
Time Frame: week 11
|
Hospital Anxiety and Depression Scale (HADS)
|
week 11
|
|
Stress
Time Frame: week 11
|
Perceived Stress Scale (PSS)
|
week 11
|
|
Compliance
Time Frame: week 11
|
Medication Adherence Report Scale (MARS)
|
week 11
|
|
Adverse events
Time Frame: week 11
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
week 11
|
|
Menopausal smptoms
Time Frame: week 23
|
Menopause Rating Scale (MRS)
|
week 23
|
|
Genaeral health-related quality of life
Time Frame: week 23
|
Functional Assessment of Cancer Therapy - General Questionaire (FACT-G)
|
week 23
|
|
Spiritual health-related quality of life
Time Frame: week 23
|
Functional Assessment of Cancer Therapy - Spirutual Subscale (FACT-SP)
|
week 23
|
|
Fatigue
Time Frame: week 23
|
Functional Assessment of Cancer Therapy - Fatigue Subscale (FACT-F)
|
week 23
|
|
Mental wellbeing
Time Frame: week 23
|
Hospital Anxiety and Depression Scale (HADS)
|
week 23
|
|
Stress
Time Frame: week 23
|
Perceived Stress Scale (PSS)
|
week 23
|
|
Compliance
Time Frame: week 23
|
Medication Adherence Report Scale (MARS)
|
week 23
|
|
Adverse Events
Time Frame: week 23
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
week 23
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mindfulness
Time Frame: week 11
|
Conscious Presence and Self Control Scale (CPSC)
|
week 11
|
|
Social Support
Time Frame: week 11
|
Berlin Social Support Scale (BSSS)
|
week 11
|
|
Expectation
Time Frame: week 0
|
Visual Analogue Scale (VAS)
|
week 0
|
|
Statisfaction
Time Frame: week 11
|
Client Satisfaction Questionnaire (CSQ)
|
week 11
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Gustav Dobos, Prof. MD, Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 15-6578-BO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.